Severe Combined Immunodeficiency Clinical Trial
Official title:
Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (Elapegademase-lvlr) Treatment in ADA-SCID Patients Requiring Enzyme Replacement Therapy
Verified date | April 2023 |
Source | Chiesi Farmaceutici S.p.A. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
This registry is conducted in patients with adenosine deaminase severe combined immune deficiency (ADA-SCID) treated with Revcovi™ to collect periodic clinical and biochemical data on safety and dose adjustment.
Status | Completed |
Enrollment | 32 |
Est. completion date | January 18, 2023 |
Est. primary completion date | January 18, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 0 Months to 65 Years |
Eligibility | Inclusion Criteria: - Patients currently receiving chronic ERT with Adagen® and transitioned/transitioning to Revcovi; - Infants diagnosed via newborn screening and definitive testing for ADA deficiency prescribed Revcovi; - Patients receiving Revcovi while preparing for Hematopoietic Stem Cell Transplant (HSCT) or Hematopoietic Stem Cell Gene Therapy (HSCGT) - Patients who decline, are ineligible or do not respond to HSCT or HSC-GT and resume/start Revcovi. Exclusion Criteria: - Any condition that, in the opinion of the Investigator, makes the patient unsuitable for the study. |
Country | Name | City | State |
---|---|---|---|
United States | UBMD Pediatrics Outpatient Center | Buffalo | New York |
United States | Duke University Hospital | Durham | North Carolina |
United States | Penn State Children's Hospital | Hershey | Pennsylvania |
United States | University of California Los Angeles | Los Angeles | California |
United States | Le Bonheur Children's Hospital | Memphis | Tennessee |
United States | Children's Minnesota | Minneapolis | Minnesota |
United States | Childrens Hospital of New Orleans | New Orleans | Louisiana |
United States | UPMC Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania |
United States | St. Louis Children's Hospital - Washington University School of Medicine | Saint Louis | Missouri |
United States | University of South Florida Allergy Immunology Clinic | Saint Petersburg | Florida |
United States | Allergy & Asthma Medical Group and Research Center, A P.C. | San Diego | California |
United States | UCSF - University of California | San Francisco | California |
United States | Seattle Children's | Seattle | Washington |
United States | Children's National | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Chiesi Farmaceutici S.p.A. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Deoxyadenosine nucleotides (dAXP) activity | Total trough erythrocyte dAXP activity | Month 24 | |
Primary | ADA activity | Trough plasma ADA activity | Month 24 | |
Secondary | Immune status (SSA/PI) | Absolute lymphocyte count and subset B, T, and NK analysis.
Immunoglobulin (Ig) concentrations (IgG, IgA, and IgM). Measurement of immune response at Investigator discretion. |
Month 24 | |
Secondary | Clinical status | Infections (clinically or microbiologically documented) Incidence and duration of hospitalizations Growth for patients < 18 years old Overall survival through the end of study | Month 24 | |
Secondary | Safety assessed by determining adverse events (AEs), serious adverse events (SAEs) | Assessed by determining adverse events (AEs), serious adverse events (SAEs), clinical signs and symptoms from physical examinations, and laboratory examinations | Month 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00006335 -
Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID
|
N/A | |
Not yet recruiting |
NCT02231983 -
Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China
|
N/A | |
Active, not recruiting |
NCT03597594 -
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)
|
Phase 1/Phase 2 | |
Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
Completed |
NCT00001255 -
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study
|
N/A | |
Recruiting |
NCT05651113 -
The Experience of Screening for SCID
|
||
Completed |
NCT00794508 -
MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID
|
Phase 2 | |
Recruiting |
NCT03538899 -
Autologous Gene Therapy for Artemis-Deficient SCID
|
Phase 1/Phase 2 | |
Recruiting |
NCT05298930 -
Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT01821781 -
Immune Disorder HSCT Protocol
|
Phase 2 | |
Completed |
NCT00845416 -
Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population
|
N/A | |
Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
Recruiting |
NCT01019876 -
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
|
Phase 2/Phase 3 | |
Completed |
NCT03513328 -
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02177760 -
Sirolimus Prophylaxis for aGVHD in TME SCID
|
Phase 2 | |
Recruiting |
NCT00695279 -
Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
|
||
Completed |
NCT01420627 -
EZN-2279 in Patients With ADA-SCID
|
Phase 3 | |
Terminated |
NCT02127892 -
SCID Bu/Flu/ATG Study With T Cell Depletion
|
Phase 1/Phase 2 | |
Completed |
NCT04246840 -
Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft
|
||
Completed |
NCT01529827 -
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 |